Only 7.1% of U.S. adults with cancer enroll in treatment trials (JCO, 2024), a bottleneck that slows drug development and limits access to targeted therapies. Proscia, a Philadelphia-based digital pathology company, aims to address that dynamic with its new tool, Aperture, which uses AI to flag potential candidates right at the point of diagnosis by… The post Proscia launches ‘Aperture’ AI platform to accelerate clinical trial recruitment at point of diagnosis appeared first on Drug Dis...
